Cambium Bio Limited
Cambium Bio Limited
Your view on CMB.AX
Overview
What the company does, where it operates, and who runs it.
About Cambium Bio Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Karolis Rosickas
- Headquarters
- Unit 2.06/31 Lexington Dr, Bella Vista, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Karolis Rosickas
- Headquarters
- Unit 2.06/31 Lexington Dr, Bella Vista, NSW, AU
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease.
The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cambium Bio Limited. Starting points for Cambium Bio Limited: EPS -AUD 0.24, beta -0.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Cambium Bio Limited. Cambium Bio Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cambium Bio Limited. Trailing twelve-month EPS for Cambium Bio Limited stands at -AUD 0.24. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.00 | −AUD 0.00 |
| Lowest estimate | −AUD 0.00 | −AUD 0.00 |
| Highest estimate | −AUD 0.00 | −AUD 0.00 |
| Number of analysts | 1 | 1 |
| A year ago | −AUD 0.171 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 795244.00 | AUD 2.19M |
| Lowest estimate | AUD 795244.00 | AUD 2.19M |
| Highest estimate | AUD 795244.00 | AUD 2.19M |
| Number of analysts | 1 | 1 |
| A year ago | AUD 641638.00 | — |
| Growth vs a year ago | +23.9% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cambium Bio Limited. Cambium Bio Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| CAZ.AXCazaly Resources Limited | Basic Materials | Industrial Materials | — | ||
| CHM.AXChimeric Therapeutics Limited | Healthcare | Biotechnology | — | ||
| CPN.AXCaspin Resources Limited | Basic Materials | Industrial Materials | — | ||
| CVR.AXCavalier Resources Limited | Basic Materials | Gold | — | ||
| IMM.AXImmutep Limited | Healthcare | Biotechnology | — | ||
| KURAKura Oncology, Inc. | Healthcare | Biotechnology | $674.4M | ||
| OLMAOlema Pharmaceuticals, Inc. | Healthcare | Biotechnology | $618.5M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| PYC.AXPYC Therapeutics Limited | Healthcare | ASX | — | ||
| OBXObsidian Therapeutics Inc. | Healthcare | NASDAQ | $12.7M | ||
| OCC.AXOrthocell Limited | Healthcare | ASX | — | ||
| OCEAOcean Biomedical, Inc. | Healthcare | PNK | $1.2M | ||
| OCGNOcugen, Inc. | Healthcare | NASDAQ | $250.8M | ||
| OCSOculis Holding AG | Healthcare | NASDAQ | $456.2M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cambium Bio Limited.